Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
Top Cited Papers
- 5 October 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 26 (12), 1859-1864
- https://doi.org/10.1038/s41591-020-1063-5
Abstract
Comprehensive genomic profiling enables genomic biomarker detection in advanced solid tumors. Here, to evaluate the utility of circulating tumor DNA (ctDNA) genotyping, we compare trial enrollment using ctDNA sequencing in 1,687 patients with advanced gastrointestinal (GI) cancer in SCRUM-Japan GOZILA (no. UMIN000016343), an observational ctDNA-based screening study, to enrollment using tumor tissue sequencing in the same centers and network (GI-SCREEN, 5,621 patients). ctDNA genotyping significantly shortened the screening duration (11 versus 33 days, P < 0.0001) and improved the trial enrollment rate (9.5 versus 4.1%, P < 0.0001) without compromising treatment efficacy compared to tissue genotyping. We also describe the clonal architecture of ctDNA profiles in ~2,000 patients with advanced GI cancer, which reinforces the relevance of many targetable oncogenic drivers and highlights multiple new drivers as candidates for clinical development. ctDNA genotyping has the potential to accelerate innovation in precision medicine and its delivery to individual patients.Keywords
This publication has 34 references indexed in Scilit:
- Multiple Roles of APC and its Therapeutic Implications in Colorectal CancerJNCI Journal of the National Cancer Institute, 2017
- The current status and problems confronted in delivering precision medicine in Japan and EuropeCurrent Problems in Cancer, 2017
- Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical TrialThe Journal of Molecular Diagnostics, 2017
- Integrated genomic characterization of oesophageal carcinomaNature, 2017
- Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNAClinical Cancer Research, 2016
- Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancerOncotarget, 2016
- Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocolAnnals of Oncology, 2016
- Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)Nature Reviews Gastroenterology & Hepatology, 2016
- Patients with Advanced Non–Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials?Journal of Thoracic Oncology, 2016
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012